Envestnet Asset Management Inc. Cuts Position in VanEck Biotech ETF (NASDAQ:BBH)

Envestnet Asset Management Inc. cut its holdings in VanEck Biotech ETF (NASDAQ:BBH) by 56.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,408 shares of the company’s stock after selling 1,837 shares during the quarter. Envestnet Asset Management Inc.’s holdings in VanEck Biotech ETF were worth $221,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new stake in VanEck Biotech ETF in the fourth quarter worth about $32,000. SBI Securities Co. Ltd. purchased a new position in VanEck Biotech ETF in the 4th quarter worth about $81,000. Wilmington Savings Fund Society FSB bought a new stake in VanEck Biotech ETF during the 3rd quarter valued at $166,000. Commonwealth Retirement Investments LLC bought a new stake in shares of VanEck Biotech ETF in the fourth quarter valued at about $215,000. Finally, Independent Advisor Alliance bought a new stake in shares of VanEck Biotech ETF in the 4th quarter valued at about $250,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Up 0.7 %

Shares of NASDAQ BBH opened at $144.68 on Thursday. The stock’s fifty day simple moving average is $153.58 and its two-hundred day simple moving average is $160.53. VanEck Biotech ETF has a 12-month low of $135.34 and a 12-month high of $183.64. The stock has a market capitalization of $331.32 million, a PE ratio of 31.41 and a beta of 0.85.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.